{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-038570","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.257833+00:00","generated_at":"2026-05-17T17:31:30.768717+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Avalo Q2 2025 net loss $20.8M; cash $113.3M; Phase 2 LOTUS >75% enrolled, topline mid-2026","bullets":["Net loss of $20.8M in Q2 2025 ($1.92 per share) compared to net income of $98.5M ($4.21 basic EPS) in Q2 2024, driven by warrant-related items.","Cash and short-term investments $113.3M as of June 30, 2025; expected to fund operations into 2028.","Phase 2 LOTUS trial (AVTX-009 in hidradenitis suppurativa) enrollment >75% complete; topline data expected mid-2026.","R&D expenses increased to $14.1M from $4.6M, largely due to the Phase 2 LOTUS trial.","Rita Jain, M.D. appointed to Board of Directors; brings clinical development and regulatory experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-038570","json":"https://secwatch.observer/filing/0001628280-25-038570.json","markdown":"https://secwatch.observer/filing/0001628280-25-038570.md","text":"https://secwatch.observer/filing/0001628280-25-038570.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828025038570/0001628280-25-038570-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828025038570/avtx-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:31:30.768717+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}